$2.96 Billion is the total value of Avoro Capital Advisors LLC's 43 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMMU | IMMUNOMEDICS INC | $330,260,000 | -36.3% | 24,500,000 | 0.0% | 11.15% | -26.8% | |
| ARGX | ARGENX SEsponsored adr | $123,365,000 | -17.9% | 936,500 | 0.0% | 4.16% | -5.7% | |
| CNST | CONSTELLATION PHARMACEUTICALS INC | $114,720,000 | -33.3% | 3,650,000 | 0.0% | 3.87% | -23.3% | |
| CUE | CUE BIOPHARMA INC | $26,535,000 | -10.6% | 1,870,000 | 0.0% | 0.90% | +2.8% | |
| MDGL | MADRIGAL PHARMACEUTICALS INC | $23,299,000 | -26.7% | 349,000 | 0.0% | 0.79% | -15.8% | |
| ALLO | ALLOGENE THERAPEUTICS INC | $21,940,000 | -25.2% | 1,128,594 | 0.0% | 0.74% | -13.9% | |
| MRNS | MARINUS PHARMACEUTICALS INC | $12,586,000 | -6.0% | 6,200,000 | 0.0% | 0.42% | +8.1% | |
| BDSI | BIODELIVERY SCIENCES INTL | $11,370,000 | -40.0% | 3,000,000 | 0.0% | 0.38% | -31.1% | |
| CBAY | CYMABAY THERAPEUTICS INC | $8,140,000 | -24.5% | 5,500,000 | 0.0% | 0.28% | -13.2% | |
| FENC | FENNEC PHARMACEUTICALS INC | $6,570,000 | -8.3% | 1,105,999 | 0.0% | 0.22% | +5.7% | |
| ALIMERA SCIENCES INC | $1,597,000 | -49.3% | 415,999 | 0.0% | 0.05% | -41.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-14 |
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.